Ingenol Disoxate

Summary

Ingenol Disoxate (CHEMBL3989918) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including actinic keratosis and acne.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 499.6 Da · C28H37NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989918
Name	Ingenol Disoxate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	57410862
Molecular formula	C28H37NO7
Molecular weight	499.6
InChIKey	GLIUZQUNUNICGS-XUBYYPQFSA-N

SMILES: CCC1=C(C(=NO1)CC)C(=O)O[C@H]2C(=C[C@@]34[C@@]2([C@@H](C(=C[C@H](C3=O)[C@H]5[C@H](C5(C)C)C[C@H]4C)CO)O)O)C

IUPAC name: [(1S,4S,5S,6R,9S,10R,12R,14R)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,11,14-tetramethyl-15-oxo-4-tetracyclo[7.5.1.01,5.010,12]pentadeca-2,7-dienyl] 3,5-diethyl-1,2-oxazole-4-carboxylate

Also known as: Disoxate d’ingenol, Disoxato de ingenol, Ingenol disoxate, LEO 43204, LEO-43204, Leo43204, LEO43204, INGENOL DISOXATE

Patent coverage: 5 distinct patent families (11 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
actinic keratosis	3	MONDO:0005173	EFO:0002496
acne	2	MONDO:0011438	EFO:0003894

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02100813	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
NCT02120456	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
NCT02305888	PHASE2	COMPLETED	Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
NCT02575950	PHASE2	COMPLETED	Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
NCT02650505	PHASE1	COMPLETED	A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).